![](https://www.sciencedaily.com/images/scidaily-icon.png)
Team marks milestone in progress toward investigational new drug for triple-negative breast cancer
A new compound developed by researchers at MUSC Hollings Cancer Center shows promise in overcoming chemotherapy resistance in triple-negative breast cancer -- and could potentially be applied to fibrotic conditions like liver fibrosis or pulmonary fibrosis …